Gilead Sciences Inc.
Gilead Sciences Elects New Board Members and Approves Key Proposals at 2026 Annual Meeting
Summary
Gilead Sciences, Inc. held its 2026 annual meeting of stockholders on April 30, 2026. The meeting saw the election of nine new directors, the ratification of Ernst & Young LLP as the independent registered public accounting firm, and the approval of the amended Gilead Sciences, Inc. 2022 Equity Incentive Plan. Stockholder proposals regarding an independent Board Chair policy, the impact of extended patent exclusivities on patient access, and the risks of ESG and DEI executive compensation metrics were not approved.
Profitelligence Alerts
Get alerts for GILD
Be first to know when Gilead Sciences Inc. files with the SEC.
Filing Categories
Advertisement
About Gilead Sciences Inc.
Gilead Sciences Inc. is a biopharmaceutical company that focuses on researching, developing, and commercializing innovative medicines in areas of unmet medical need. It is globally recognized for its distinguished work, particularly in the treatment of HIV, liver diseases such as hepatitis B and C, and various forms of cancer. The company's portfolio includes groundbreaking antiviral therapies and a robust pipeline of investigational drugs. Headquartered in Foster City, California, Gilead Sciences Inc. significantly contributes to the healthcare sector by extending the lives of patients with serious illnesses worldwide. Through strategic partnerships and continuous innovation, Gilead remains at the forefront of modern medicine, enhancing its role in the global pharmaceutical market.
Official SEC Documents
Advertisement